SCHEMBL846033

SCHEMBL846033

CCCCCc1ccc(C=CC(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.69
KDM4E B2RXH2 1/20 0.69
NPC1 O15118 1/20 0.69
HPGD P15428 1/20 0.69
CASP3 P42574 1/20 0.69
RAB9A P51151 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
SENP8 Q96LD8 1/20 0.69
SENP7 Q9BQF6 1/20 0.69
SENP6 Q9GZR1 1/20 0.69
ATG4B Q9Y4P1 12/20 0.65
PLA2G1B P04054 11/20 0.65
THRA P10827 2/20 0.63
THRB P10828 2/20 0.63
CYP1A2 P05177 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
RECQL P46063 1/20 0.63
TRPM2 O94759 2/20 0.59
CYSLTR2 Q9NS75 2/20 0.59
CYSLTR1 Q9Y271 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL846032 1.00 ALDH1A1 (0.69) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL11765995 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL19460591 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL3684326 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL6279557 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL6287182 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL6279559 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
Hydrochloric Acid SCHEMBL11766313 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL489898 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3
SCHEMBL3025061 0.98 ALDH1A1 (0.67) ALDH1A1KDM4ENPC1HPGDCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102701958-B Novel antibacterial agent acyl phenoxyacetic acid, acyl cinnamic acid and preparation method thereof UNIV CHANGZHOU 2014-12-31 CN disclosed
CN-102701958-B Novel antibacterial agent acyl phenoxyacetic acid, acyl cinnamic acid and preparation method thereof UNIV CHANGZHOU 2014-12-31 CN disclosed
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 US disclosed
CN-102701958-A Novel antibacterial agent acyl phenoxyacetic acid, acyl cinnamic acid and preparation method thereof UNIV CHANGZHOU 2012-10-03 CN disclosed
CN-102701958-A Novel antibacterial agent acyl phenoxyacetic acid, acyl cinnamic acid and preparation method thereof UNIV CHANGZHOU 2012-10-03 CN disclosed
EP-1603883-B1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-03-28 EP disclosed
EP-2308848-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor Janssen Pharmaceutica NV (BE) 2011-04-13 EP disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 US disclosed
EP-1603883-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2005-12-14 EP disclosed
US-6911468-B2 Tyrosine phosphatase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-06-28 US disclosed
EP-1284260-A1 TYROSINE PHOSPHATASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-02-19 EP disclosed
US-5459134-A Leukotriene antagonists; phospholipase, 5-alpha-reductase, and aldose reductase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1995-10-17 US disclosed
US-5446058-A Leukotriene antagonists, 5-alpha-reductase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-29 US disclosed
EP-0463638-B1 Aminophenyl derivatives ONO PHARMACEUTICAL CO (JP) 1995-05-24 EP disclosed
EP-0173516-B1 (Fused)benz(thio)amides ONO PHARMACEUTICAL CO (JP) 1993-12-01 EP disclosed
US-4939141-A (Fused) benz (thio) amides and pharmaceutical compositions, thereof ONO PHARMACEUTICAL CO., LTD. (JP) 1990-07-03 US disclosed
US-4847275-A ENZYME INHIBITOR, LEUKOTRIENE ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 1989-07-11 US disclosed
US-4780469-A (Fused) benz(thio)amides and pharmaceutical use ONO PHARMACEUTICAL CO., LTD. (JP) 1988-10-25 US disclosed
EP-0173516-A2 (Fused)benz(thio)amides ONO PHARMACEUTICAL CO., LTD. (JP) 1986-03-05 EP disclosed
US-4061587-A Liquid crystalline cinnamic acid esters HOFFMANN-LA ROCHE INC. (US) 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 ALDH1A1 1216/4885KDM4E 3604/4885NPC1 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.